Moreover, the proliferation of pancreatic cancer cells and their resistance to olaparib were found to increase upon NLRP4 complementation when compared to the levels in cells with NLRP4 knockdown (Fig. 9f-g). This evidence concerns the gene NLRP4 and pancreatic neoplasm.